Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.
Awada H, Mahfouz RZ, Kishtagari A, Kuzmanovic T, Durrani J, Kerr CM, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, Maciejewski JP, Saunthararajah Y. Awada H, et al. Among authors: saunthararajah y. Br J Haematol. 2020 Mar;188(6):924-929. doi: 10.1111/bjh.16281. Epub 2019 Nov 17. Br J Haematol. 2020. PMID: 31736067 Free PMC article.
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP. Jiang Y, et al. Among authors: saunthararajah y. Blood. 2009 Feb 5;113(6):1315-25. doi: 10.1182/blood-2008-06-163246. Epub 2008 Oct 2. Blood. 2009. PMID: 18832655 Free PMC article.
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Advani AS, Tiu R, Saunthararajah Y, Maciejewski J, Copelan EA, Sobecks R, Sekeres MA, Bates J, Rush ML, Tripp B, Salvado A, Noon E, Howard M, Jin T, Hsi E, Egorin MJ, Lim K, Cotta CV, Price C, Kalaycio M. Advani AS, et al. Among authors: saunthararajah y. Leuk Res. 2010 Dec;34(12):1622-6. doi: 10.1016/j.leukres.2010.03.021. Epub 2010 Apr 27. Leuk Res. 2010. PMID: 20427086 Clinical Trial.
Noncytotoxic differentiation treatment of renal cell cancer.
Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y. Negrotto S, et al. Among authors: saunthararajah y. Cancer Res. 2011 Feb 15;71(4):1431-41. doi: 10.1158/0008-5472.CAN-10-2422. Epub 2011 Feb 8. Cancer Res. 2011. PMID: 21303982 Free PMC article.
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, Desimone J, Saunthararajah Y. Lavelle D, et al. Among authors: saunthararajah y. Blood. 2012 Feb 2;119(5):1240-7. doi: 10.1182/blood-2011-08-371690. Epub 2011 Dec 7. Blood. 2012. PMID: 22160381 Free PMC article.
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA. Bejanyan N, et al. Among authors: saunthararajah y. Cancer. 2012 Aug 15;118(16):3968-76. doi: 10.1002/cncr.26741. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180010 Free article. Clinical Trial.
Polycomb segment myeloid malignancies.
Saunthararajah Y, Maciejewski J. Saunthararajah Y, et al. Blood. 2012 Feb 2;119(5):1097-8. doi: 10.1182/blood-2011-12-391268. Blood. 2012. PMID: 22308277 Free article.
163 results